NEOS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.95 SEK | +3.94% |
|
+1.06% | -56.82% |
| Apr. 15 | Air Astana Partner with Italy-based Neos | MT |
| Mar. 22 | NeoDynamics AB Announces Appointment of Matilda Salén as Its New Chief Executive Officer | CI |
| Sales 2023 | 751K 68.57K | Sales 2024 * | 32M 2.92M | Capitalization | 30.98M 2.83M |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 | 18.2 x |
| Net cash position 2023 | 2.3M 210K | Net cash position 2024 * | 3.9M 356K | EV / Sales 2024 * | 0.85 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 9 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 0.93% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +3.94% | ||
| 1 week | +1.06% | ||
| 3 months | -43.45% | ||
| 6 months | -75.32% | ||
| Current year | -56.82% |
1 week
0.87
0.95
1 month
0.850.95
Current year
0.852.30
1 year
0.8562.70
3 years
0.85369.00
5 years
0.85650.00
10 years
0.85650.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 22-01-31 | |
| Chief Tech/Sci/R&D Officer | - | 09-01-31 | |
Magnus Olsen
COO | Chief Operating Officer | - | 12-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 17-12-31 | |
Claes Pettersson
BRD | Director/Board Member | 71 | 14-12-31 |
| Director/Board Member | - | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.95 | +3.94% | 13,047 |
| 24-04-26 | 0.914 | -2.35% | 2,086 |
| 24-04-25 | 0.936 | +4.93% | 4,497 |
| 24-04-24 | 0.892 | -4.90% | 7,998 |
| 24-04-23 | 0.938 | -0.21% | 10,272 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 10:36 am EDT
More quotes
NeoDynamics AB (publ) is a Sweden-based company engaged in the medical industry. The Company focuses on developing and commercializing products for breast cancer screening, imaging, and breast cancer treatments. The Companyâs product NeoNavia, enables a pulse biopsy system for ultrasound guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling tissue samples from both breasts and lymph nodes. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at clinics in United Kingdom, Germany, and Sweden.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -56.82% | 2.83M | |
| -12.42% | 19.22B | |
| -46.59% | 2.63B | |
| +17.50% | 1.86B | |
| -0.58% | 1.66B | |
| +25.36% | 1.23B | |
| -8.67% | 1.05B | |
| -21.91% | 894M | |
| -4.42% | 740M | |
| -17.51% | 687M |
- Stock Market
- Equities
- NEOD Stock
